A detailed history of Black Rock Inc. transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,829,978 shares of LYRA stock, worth $509,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,829,978
Previous 151,919 1762.82%
Holding current value
$509,396
Previous $944,000 16.1%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.26 - $6.25 $696,295 - $16.7 Million
2,678,059 Added 1762.82%
2,829,978 $792,000
Q1 2024

May 10, 2024

BUY
$4.55 - $6.53 $187,105 - $268,526
41,122 Added 37.11%
151,919 $944,000
Q4 2023

Feb 13, 2024

BUY
$2.82 - $5.24 $178,548 - $331,770
63,315 Added 133.35%
110,797 $580,000
Q3 2023

Nov 13, 2023

SELL
$2.95 - $4.8 $3,339 - $5,433
-1,132 Reduced 2.33%
47,482 $185,000
Q2 2023

Aug 11, 2023

BUY
$1.98 - $4.33 $14,323 - $31,323
7,234 Added 17.48%
48,614 $199,000
Q1 2023

May 12, 2023

BUY
$1.95 - $3.09 $2,468 - $3,911
1,266 Added 3.16%
41,380 $83,000
Q4 2022

Feb 13, 2023

BUY
$2.44 - $5.42 $2,681 - $5,956
1,099 Added 2.82%
40,114 $125,000
Q3 2022

Nov 14, 2022

SELL
$4.95 - $6.6 $12,706 - $16,942
-2,567 Reduced 6.17%
39,015 $196,000
Q2 2022

Aug 12, 2022

BUY
$4.12 - $7.51 $93,013 - $169,545
22,576 Added 118.78%
41,582 $235,000
Q1 2022

May 12, 2022

BUY
$3.5 - $5.36 $2,565 - $3,928
733 Added 4.01%
19,006 $77,000
Q4 2021

Feb 10, 2022

BUY
$4.22 - $9.41 $1,920 - $4,281
455 Added 2.55%
18,273 $80,000
Q3 2021

Nov 09, 2021

SELL
$6.06 - $9.43 $13,950 - $21,707
-2,302 Reduced 11.44%
17,818 $163,000
Q2 2021

Aug 11, 2021

BUY
$6.91 - $12.59 $139,029 - $253,310
20,120 New
20,120 $161,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.